Alchemia Limited (ACL)

Alchemia Limited (ASX: ACL) is a drug discovery and development company. Its lead drug fondaparinux is a generic version of GlaxoSmithKline’s Arixtra®, a synthetic anticoagulant mainly used for preventing deep vein thrombosis.

Fondaparinux was approved by the FDA and launched in July 2011 in the USA by Alchemia’s marketing partner Dr Reddy’s Laboratories. Alchemia’s asset pipeline is built on two platform technologies: HyACT® (targeted cancer delivery) and VAST® (drug discovery). The lead product from the HyACT platform is HA-Irinotecan for which a Phase III clinical trial in metastatic colorectal cancer is currently in progress.

 

Location:
Melbourne, Australia
Market Cap:
$4 million
No. Shares:
324,723,621
Sector:
Health Care
Website:
www.alchemia.com.au
Share Price & Volume

Additional Research

Nomura Equity Research Report 2 Apr 2012

Southern Cross Equities Report  11 Jul 2011

 

AusBiotech Member
AusBiotech Member

DISCLAIMER: Orient Capital Pty Ltd has taken all reasonable care in publishing the information contained in this Open Briefing®; furthermore, the entirety of this Open Briefing® has been approved for release to the market by the participating company. It is information given in a summary form and does not purport to be complete. The information contained is not intended to be used as the basis for making any investment decision and you are solely responsible for any use you choose to make of the information. We strongly advise that you seek independent professional advice before making any investment decisions. Orient Capital Pty Ltd is not responsible for any consequences of the use you make of the information, including any loss or damage you or a third party might suffer as a result of that use.